# Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

> **NCT04827745** · PHASE2 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 2 (actual)

## Conditions studied

- Mixed Phenotype Acute Leukemia (MPAL)
- Measurable Residual Disease (MRD)

## Interventions

- **DRUG:** BLINCYTO (Blinatumomab)

## Key facts

- **NCT ID:** NCT04827745
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-11
- **Primary completion:** 2025-05-22
- **Final completion:** 2025-05-22
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827745, "Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04827745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*